Analysis
Retension Pharmaceuticals, Inc. filed a second S-1/A amendment with the SEC on Oct. 7, 2026, just two days after filing its first amendment on Oct. 5, according to SEC filings. Pulse first covered Retension's IPO registration on Sept. 21, when it filed its original S-1 jointly covered alongside fellow biotech issuer TRex Bio.
What changed
The filing sequence has moved quickly: a confidential DRS/A submitted June 16, the public S-1 filed Sept. 18, Amendment No. 1 on Oct. 5, and now Amendment No. 2 on Oct. 7 under the same registration number, 333-299024. Both amendments list the company's address in Falls Church, Virginia, with Eric Keller as CEO. Neither amendment discloses a share count, price range or expected proceeds, so the offering remains in SEC review rather than nearing a priced close.
Two amendments within two days is a faster cadence than the roughly three-week gaps common among SEC comment-letter cycles for smaller biotech issuers, suggesting the registration is moving through routine review rather than stalling on a substantive SEC objection. The filings don't specify what prompted either amendment, so whether the changes are financial, legal or purely administrative isn't yet public.
